uniQure N.V. Aktie News

uniQure (QURE) is upgraded to Buy following strong 36-month high-dose AMT-130 data for Huntington's disease, showing significant slowing of disease progression. QURE's AMT-130 demonstrated robust clinical benefits, including improved daily activities, cognition, and motor function, despite small sample size and external control limitations. Financially, QURE is well-positioned with over $700 mi...

Momentum investors rely on a combination of astute analysis and timing to maximize gains. While this approach can carry a fair degree of risk, the allure of identifying a fast-growing stock and joining a rally that has room to continue is powerful.

uniQure surged over 300% following strong 3-year data from its Huntington's trial, yet remains undervalued due to skepticism over trial size and the use of external controls. AMT-130's apparent efficacy and prior alignment with the FDA on accelerated approval position AMT-130 for commercialization in the near term. Relatively modest volumes are needed to justify uniQure's current valuation, mea...

In one of the most incredible single-day moves this year, biotechnology stock uniQure NASDAQ: QURE surged by 284% on Sept. 24. This came as the firm released fantastic clinical results for its developmental medicine, AMT-130.

LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 6,736,841 ordinary shares at a public offering price of $47.50 per share, which includes 947,368 ordinary s...

LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 5,789,473 ordinary shares at a public offering price of $47.50 per share, and, in lieu of ordinary shares t...

UniQure announced groundbreaking results for AMT-130, its gene therapy targeting Huntington's disease, showing a statistically significant 75% reduction in disease progression in a pivotal Phase I/II trial. ((UniQure's Press Release, Sep 24, 2025)) This milestone marks the first therapy to meaningfully slow Huntington's progression and positions UniQure to unlock value across revenue growth, ma...

A ClearPoint Neuro's medical device plays an important role in UniQure's effort to battle Huntington's disease.